Efficacy of Low (30ml) Versus Full Dose (100ml) Contrast CT Pulmonary Angiography in Detecting Emboli
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01935141 |
Recruitment Status
:
Withdrawn
(Staffing difficulties to run project.)
First Posted
: September 4, 2013
Last Update Posted
: November 8, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Multiple Pulmonary Emboli | Procedure: Low-Dose IV Contrast Device: Siemens Sensation 64-MDCT scanner. Drug: Visipaque 320 non-ionic isoosmolar contrast agent | Not Applicable |
Potential participants in the study will have been referred to the radiology section for a CTPA for a suspected pulmonary embolus. The radiologist will review the patient's record in CPRS, as is done routinely in this situation. Patients with class 3 or 4 CHF, supraventricular tachycardia, Serum Creatinine >1.5 mg/dl (>1.3 mg/dl female), history of contrast allergy, or unable to give informed consent will be excluded from both arms of the study. Patients with serum creatinine >1.28 mg/dl require referring physician approval. If the participant appears to qualify for the study then the study physician will contact the referring physician and inform him/her of the study. If the referring physician is agreeable then either the radiologist or the referring physician will approach the patient, either at the bedside or in the radiology clinic to determine if the patient is interested in participating in the study. If so, a study radiologist will begin the informed consent process. After informed consent is obtained the subject will be computer randomized to either the new low-dose or full-dose technique protocols. A total of 220 studies (110 per group) will be performed.
Multidetector CT Scan: All CT examinations will be performed on the Siemens Sensation 64-MDCT scanner. Visipaque (Iodixanol) 320 non-ionic isoosmolar contrast agent will be used in all contrast examinations followed by a subsequent injection of normal saline. An informed written consent for the injection of IV contrast will be obtained prior to all CT examinations. Safe venous access will be obtained via either an antecubital vein or a central venous line. For low dose CT pulmonary angiograms, 30 ml of IV Radio Contrast Material (RCM) will be injected at a flow rate of 5 ml/second followed by an injection of 20 ml of normal saline at 5ml/second. The region of interest (ROI) will be the superior vena cava (SVC) at the approximate level of the aortic arch. The scan will be triggered to begin at 75 Hounsfield units (HU). For Full dose CT pulmonary angiograms, 100 ml of IV RCM will be injected at a flow rate of 5ml/sec. The ROI will be the main pulmonary artery. The scan will be triggered at 120 HU. One mm contiguous axial spiral scans will be obtained from the apex of the lung through the adrenals. Reformatted 1.5 mm axial, 3 mm axial, 1.5 mm coronal and sagittal images will be obtained. All images will be uploaded to the AGFA Picture Archiving Communication System (PACS) workstation for interpretation. The costs of all CT scans and RCM will be covered by the Department of Imaging as the majority of the studies are part of routine clinical care.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Diagnostic |
Official Title: | Efficacy Of Low(30 Ml) Versus Full Dose (100 Ml)Contrast CT Pulmonary Angiography Performed On 64 Multi-Detector CT In Detecting Emboli |
Study Start Date : | January 2016 |
Estimated Primary Completion Date : | December 2017 |
Estimated Study Completion Date : | December 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Low-Dose IV Contrast
A single intravenous dose of 30 ml of Visipaque 320 non-ionic isoosmolar contrast agent will be given for each CT scan. The CT scan will be performed using a Siemens Sensation 64-MDCT scanner.
|
Procedure: Low-Dose IV Contrast
A single intravenous dose of 30 ml of Visipaque (Iodixanol) 320 non-ionic isoosmolar contrast agent will be given for each CT scan.
Other Names:
Device: Siemens Sensation 64-MDCT scanner.
The device will be used to perform CT Pulmonary Angiograms
Drug: Visipaque 320 non-ionic isoosmolar contrast agent
Single Dose of Intravenous Iodixanol will be administered per CT scan.
Other Name: Iodixanol
|
Active Comparator: Full-Dose IV Contrast
A single intravenous dose of 100ml of Visipaque 320 non-ionic isoosmolar contrast agent will be given for each CT scan. The CT scan will be performed using a Siemens Sensation 64-MDCT scanner.
|
Procedure: Low-Dose IV Contrast
A single intravenous dose of 30 ml of Visipaque (Iodixanol) 320 non-ionic isoosmolar contrast agent will be given for each CT scan.
Other Names:
Device: Siemens Sensation 64-MDCT scanner.
The device will be used to perform CT Pulmonary Angiograms
Drug: Visipaque 320 non-ionic isoosmolar contrast agent
Single Dose of Intravenous Iodixanol will be administered per CT scan.
Other Name: Iodixanol
|
- CT Image Quality Score [ Time Frame: Within 4 weeks of the CT scan ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients referred for CT pulmonary angiogram to exclude pulmonary embolus
Exclusion Criteria:
- Class 3 or 4 Congestive Heart Failure
- Supraventricular tachycardia
- History of contrast allergy
- Unable to give informed consent
- Patients with serum creatinine >1.28 mg/dl without referring physician approval

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01935141
United States, California | |
VALosAngeles | |
Los Angeles, California, United States, 90073 |
Principal Investigator: | Bruce M. Barack, M.D. | VA Greater Los Angeles Healthcare System |
Responsible Party: | Bruce Barack, Staff Radiologist, VA Greater Los Angeles Healthcare System |
ClinicalTrials.gov Identifier: | NCT01935141 History of Changes |
Other Study ID Numbers: |
2012-101526 |
First Posted: | September 4, 2013 Key Record Dates |
Last Update Posted: | November 8, 2016 |
Last Verified: | November 2016 |
Keywords provided by Bruce Barack, VA Greater Los Angeles Healthcare System:
Pulmonary Embolus Radio Contrast Material Computed Tomography |
Additional relevant MeSH terms:
Embolism Pulmonary Embolism Embolism and Thrombosis Vascular Diseases |
Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases |